WhatsApp
backNews Article

Genesys International Announces Q2 FY2027 Unaudited Financials and Grants 3.65 Lakh Employee Stock Options at Discounted Prices

Company reports profit before tax of Rs.727.84 lakh for quarter ended September 30, 2026 and grants stock options at 48.43% to 63.90% discount to NSE closing price

Genesys International Corporation Limited released its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company also granted 3,65,000 employee stock options under its 2022 ESOP scheme with exercise prices ranging from Rs.70 to Rs.100 per share, representing a 48.43% to 63.90% discount to the November 12 closing price on NSE.

2 days ago|GENESYS+0.00%
Genesys International Corporation LimitedBSE:506109NSE:GENESYSFinancial Results

Genesys International Corporation Limited

Financial Results

Genesys International Corporation Limited disclosed its unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026, reporting a profit before tax of Rs.727.84 lakh in the quarter. The company also approved the grant of 3,65,000 employee stock options under its 2022 ESOP scheme, with exercise prices between Rs.70 to Rs.100, discounted significantly from the previous day's NSE closing price.

The Board of Directors met on November 13, 2026, approving the unaudited financial statements prepared under Indian Accounting Standards (Ind AS) and reviewed by independent auditors who expressed an unmodified conclusion.

For the quarter ended September 30, 2026, Genesys reported total income of Rs.8,001.10 lakh and total expenses of Rs.7,273.26 lakh, resulting in a profit before tax of Rs.727.84 lakh. After tax expenses, net profit was Rs.528.88 lakh. Comprehensive income including other items was Rs.586.60 lakh.

During the meeting, the company granted 3,65,000 employee stock options to eligible employees under the Genesys Employee Stock Option Scheme, 2022. This includes 4,640 options re-granted from previously lapsed options.

The stock options have exercise prices ranging from Rs.70 to Rs.100 per equity share. These exercise prices reflect a discount between 48.43% to 63.90% compared to the closing price of the company's shares on the National Stock Exchange on November 12, 2026.

Highlights

  • Unaudited standalone profit before tax stood at Rs.727.84 lakh for Q2 FY2027 ending September 30, 2026.
  • 3,65,000 employee stock options granted under 2022 ESOP, including 4,640 re-granted options.
  • Exercise prices of options range from Rs.70 to Rs.100 per share.
  • Stock option prices represent a discount of 48.43% to 63.90% compared to NSE closing price on November 12, 2026.
  • Limited review report on financial results issued by statutory auditors with unmodified conclusion.
  • Board meeting lasted from 5:00 p.m. to 6:50 p.m. IST on November 13, 2026.

Key Data Snapshot

Quarter endedSeptember 30, 2026
Profit before tax (Standalone)Rs.727.84 lakh
Profit after tax (Standalone)Rs.528.88 lakh
Total Income (Standalone)Rs.8,001.10 lakh
Employee Stock Options granted3,65,000 options
Options exercise price rangeRs.70 to Rs.100 per equity share
Discount to NSE closing price on Nov 12, 202648.43% to 63.90%
Date of Board MeetingNovember 13, 2026

What happened

  • Genesys International released unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, under Indian Accounting Standards.
  • The statutory auditor issued a limited review report with an unmodified conclusion on these financial results.
  • The company reported a profit before tax of Rs.727.84 lakh for the quarter on a standalone basis.

Key details

  • Board approved the grant of 3,65,000 employee stock options under the Genesys Employee Stock Option Scheme, 2022.
  • 4,640 of these options are re-grants of previously lapsed options under the Scheme.
  • Options were granted at exercise prices ranging between Rs.70 and Rs.100 per equity share.
  • These prices represent a discount of 48.43% to 63.90% compared to the closing price of the company’s shares on the NSE as of November 12, 2026.

Regulatory and governance context

  • The financial results comply with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  • The audit and review were conducted in accordance with Indian Accounting Standard 34 for interim financial reporting.
  • The limited review was performed as per Standard on Review Engagement 2410 issued by the Institute of Chartered Accountants of India.

More News on Financial Results

View all

Latest corporate announcements and market updates in Financial Results.

View all news
Genesys International Announces Q2 FY2027 Unaudited | Stockk News